Since private equity firm Linden Capital Partners L.L.C. acquired Flexan, the firm has been busy on the acquisition front. Its two notable moves brought Medron and IntroMed into the fold, both based in Salt Lake City.
Medron gave Flexan its first Utah location and a presence in thermoplastic extrusion, capabilities it did not have before. IntroMed LLC was a manufacturer of patented sheath introducers used in catheter placements. It also performs in-house secondary operations like overmolding, tipping, bonding and printing.
Part of integrating the new operations was improving its footprint efficiency — both with its legacy and incoming sites. The firm relocated its three Chicago-area facilities into a larger, 70,000-square-foot site in Lincolnshire, Ill, not far from its existing footprint. It quadrupled its Class 7 clean room space in the process to 20,000 square feet. Employment was unaffected.
Its legacy Flexan non-medical business still operates out of its own 65,000-square-foot facility in Chicago focused on rubber molding for industrial applications.
The firm continues to operate two locations in China, but relocated its second plant to a building next door to the main site in Suzhou.
At Salt Lake City, the firm acquired additional space within its existing operations and is set to relocate all of the surrounding production under one roof by the end of 2019 as customer approvals roll in, Fitzgerald said.
He added that each facility still has an independent quality registration, which is important in medical to avoid dependency on a single site. All, however, are aligned under the same quality systems approach.
"Part of that discipline is getting everyone involved in lean principles," Huiras said. "That resonates throughout all of our business units. Each has distinct capabilities and uniqueness, but they're all operating under the same brand and culture. Every business unit is going to have its own unique challenges, but how we manage the challenges and put the team in the right position to win has been exciting."